Program
mavacamten
Also written as “Mavacamten” and “MYK-461”.
Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.
Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 194 open or running | phase 4since Oct 27, 2023 | Dec 19, 2014 | Dec 13, 2027phase 4 · NCT07004972 |
| LianBio | 20 open or running | phase 3since Dec 13, 2021 | Oct 28, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LianBio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
- Oct 28, 2021First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT05135871 · 45 enrolled · China
- Dec 13, 2021Phase 3 study in Cardiomyopathy, HypertrophicNCT05174416 · 81 enrolled · China
TargetBeta
“Cardiac myosin inhibitor”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| omecamtiv mecarbilrule | Cytokinetics | phase 3 | 16 |
| danicamtivrule | Bristol-Myers Squibb | phase 3 | 7 |
Studies
All 2 LianBio leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05174416Cardiomyopathy, Hypertrophic · China | 3 | Completed | Mar 6, 2023 | 81 |
| NCT05135871Cardiomyopathy, Hypertrophic · China | 1 | Completed | Feb 5, 2022 | 45 |
How it is read
Names in the registry
- “Mavacamten”, 12 entries
- “mavacamten”, 5 entries
- “MYK-461”, 4 entries
Conditions, from the studies’ own filings
- Cardiomyopathy, Hypertrophic, 18 studies
- Anthrax, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.